- TRADE NAME: Ibrance (Pfizer)
- INDICATIONS: Treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (in combination with letrozole)
- CLASS: Cyclin-dependent kinase (CDK) 4/6 inhibitor
- HALF-LIFE: 29 hours
- FDA APPROVAL DATE: 02/03/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bosentan, Carbamazepine, Clarithromycin, Efavirenz, Etravirine, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Modafinil, Nafcillin, Nefazodone, Nelfinavir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Telaprevir, Telithromycin, Verapamil, Voriconazole - PREGNANCY: Can cause fetal harm
Please login to view the rest of this drug profile.
DRUG REVIEW ARTICLE
DRUG REVIEW ARTICLE #2
Click on the DRUG REVIEW ARTICLE links (above) to see two reviews of palbociclib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/20/2024